CONTROLLED-RELEASE FERTILIZER IN THE GROWTH OF Dalbergia nigra SEEDLINGS

For the realization of forest restoration projects, it is essential to produce native seedlings in quantity, also necessary that they present greater vegetative vigor and good nutritional status. In this context, the objective of this work was to analyze the growth and nutrition of phosphorus of Dalbergia nigra seedlings from two sources cultivated with doses of controlled-release fertilizer (CRF). The experimental design was in randomized blocks, arranged in a factorial scheme 2 x 4, referring to lots of two seed sources of D. nigra (Viçosa, MG and Linhares, ES) and four doses of CRF (0, 2, 4 and 8 kg m-3), with four replications and 126 seedlings per plot. At 60, 90 and 120 days after sowing, the seedlings were collected to measure the variables related to growth and nutrition. D. nigra seedlings from Linhares (ES) show better growth and dry matter production. It is recommended to dose 7.46 kg m-3 of controlled-release fertilizer for seedlings from Linhares (ES) and the dose 5.99 kg m-3 for those coming from Viçosa (MG), aiming to maximize the growth of production of seedlings of D. nigra. Increasing doses of controlled-release fertilizer allow greater accumulation of P in shoot shoots of D. nigra

State of play and future direction with NOACs: An expert consensus.

Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, VKA therapy is associated with challenges relating to dose maintenance, the need to monitor anticoagulation, and bleeding risks. The non-vitamin K oral anticoagulants (NOACs) are becoming accepted as a clear alternative to VKA therapy for both AF and VTE management. The aim of this paper was to review contemporary evidence on the safety of NOACs in both conditions. A comprehensive literature review was conducted to explore key safety issues and expert consensus was achieved from eight professionals specialised in AF and VTE care. Consensus-based statements were formulated where available evidence was weak or contradictory. The expert statements in this paper form a key overview of the safety of NOACs compared with VKA therapy, and the comparative safety of different NOACs. It is apparent that a detailed patient work-up is required in order to identify and manage individual risk factors for bleeding and thrombosis prior to NOAC therapy. Additional measures, such as dose reductions, may also be used to maintain the safety of NOACs in practice